Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved two new drugs, a combination chimeric antigen receptor (CAR) T-cell therapy improves multiple myeloma (MM) survival, and more.
A combination of humanized anti-CD19 and anti-B-cell maturation antigen (BCMA) CAR T-cell therapy resulted in a 95% response rate among patients with relapsed/refractory MM, according to a study published in The Lancet Haematology.
Recent research from the University of Massachusetts Amherst food scientists has found that consuming frying oil may worsen colon cancer and colitis. In their study, they found that feeding frying oil to mice led to heightened inflammation of the colon, tumor growth, gut leakage, and spreading of bacteria and their toxic byproducts into the circulatory system.
The FDA issued a warning to consumers not to purchase or drink Miracle or Master Mineral Solution, Miracle Mineral Supplement, MMS, Chlorine Dioxide Protocol, Water Purification Solution, and other similar products. Miracle Mineral Solution has not been approved by the FDA for any use, but these products have been promoted on social media as a remedy for treating various conditions, including cancer.
The FDA approved two new drugs: Inrebic® (fedratinib) for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis and Rozlytrek® (entrectinib), a tumor-agnostic treatment for NTRK- and ROS1-positive solid tumors.
A new study observed a shift in the incidence of obesity-associated cancers from older patients to younger ones.
In case you missed it, more hem/onc headlines are featured below:
- Johns Hopkins Researchers Find Link Between Antibiotics and Colon Cancer
- Shortcomings of New BRCA1/2 Genetic Test Recommendations
- Glioblastoma May Soon Be Diagnosed with a Simple Blood Test
- Rozlytrek vs. Vitrakvi: How Do These Cancer Drugs Compare?
- USPSTF: More Women Should be Evaluated for BRCA-related Cancer
- What Factors Cause Frequent ER Visits in Patients With Head and Neck Cancer?
- Votrient® Improves Survival for Soft-Tissue Sarcoma, Particularly After One Prior Line of Therapy
- New Study Brings Researchers Closer to Preventing Cancer Metastasis
- Prognostic Value of Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity
- Cancer Survivors Have Long-term Cardiovascular Risks
- Helping Skin Cells Differentiate May Help Treat Skin Cancer
- Melanoma Treatment with BRAF and MEK Inhibitors Increases Cardiovascular Risks
- Study: A Drug Combination that Inhibits the Growth of Pediatric Ewing Sarcoma
- Facility-Based Care is More Effective for Treating Breast-Cancer Related Lymphedema than Home-Based Care
- Pediatricians May Help Parents Quit Smoking
- A Lack of Racial Diversity Exists in Cancer Drug Clinical Trials
- Hormonal Therapy Has Protective Effect for Certain Breast Cancer Subtypes